	US 12,239,652 B2
	Composition for preventing or treating muscular diseases, or for improving muscular functions, containing ganglioside
Jae Kwan Hwang, Seoul (KR); Seung Tae Su, Seoul (KR); Jong Wook Kim, Seoul (KR); Chang Hee Kim, Seoul (KR); and Ji Hee Yoo, Gyeonggi-do (KR)
Assigned to INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSELUNIVERSITY, Seoul (KR)
Appl. No. 17/271,031
Filed by INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY, Seoul (KR)
PCT Filed Aug. 23, 2019, PCT No. PCT/KR2019/010800 § 371(c)(1), (2) Date Feb. 24, 2021, PCT Pub. No. WO2020/040615, PCT Pub. Date Feb. 27, 2020.
Claims priority of application No. 10-2018-0099447 (KR), filed on Aug. 24, 2018; and application No. 10-2019-0103779 (KR), filed on Aug. 23, 2019.
Prior Publication US 2021/0353659 A1, Nov. 18, 2021
Int. Cl. A61K 31/7032 (2006.01); A23L 33/00 (2016.01); A23L 33/125 (2016.01); A61K 31/739 (2006.01); A61P 21/06 (2006.01)

CPC A61K 31/7032 (2013.01) [A23L 33/125 (2016.08); A23L 33/40 (2016.08); A61K 31/739 (2013.01); A61P 21/06 (2018.01); A23V 2002/00 (2013.01)]

3 Claims

1. A method of increasing mRNA expression levels of mTOR and reducing mRNA expression levels of atrogin-1 and MuRF1 in muscle cells for treating cachexia or age-related sarcopenia in a subject in need thereof, comprising administering a pharmaceutical composition comprising a ganglioside as an active ingredient,

wherein the ganglioside of the pharmaceutical composition is obtainable from antler, sweet potato, colostrum, milk, or a mixture thereof,

wherein the ganglioside is selected from the group consisting of ganglioside GM1, ganglioside GD1a, ganglioside GT1b, and ganglioside GQ1b,

wherein the ganglioside GM1 is represented by Formula 3, wherein the ganglioside GD1a is represented by Formula 4, wherein the ganglioside GT1b is represented by Formula 5, wherein the ganglioside GQ1b is represented by Formula 6,